These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 32784089)

  • 1. Synthesis and biological evaluation of thiazole derivatives on basic defects underlying cystic fibrosis.
    Pesce E; Pedemonte N; Leoni A; Locatelli A; Morigi R
    Bioorg Med Chem Lett; 2020 Nov; 30(21):127473. PubMed ID: 32784089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and structure-activity relationship of aminoarylthiazole derivatives as correctors of the chloride transport defect in cystic fibrosis.
    Pesce E; Bellotti M; Liessi N; Guariento S; Damonte G; Cichero E; Galatini A; Salis A; Gianotti A; Pedemonte N; Zegarra-Moran O; Fossa P; Galietta LJ; Millo E
    Eur J Med Chem; 2015 Jun; 99():14-35. PubMed ID: 26041577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
    Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
    Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
    Yang H; Ma T
    Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unravelling the Regions of Mutant F508del-CFTR More Susceptible to the Action of Four Cystic Fibrosis Correctors.
    Amico G; Brandas C; Moran O; Baroni D
    Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31683989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview on chemical structures as ΔF508-CFTR correctors.
    Spanò V; Montalbano A; Carbone A; Scudieri P; Galietta LJV; Barraja P
    Eur J Med Chem; 2019 Oct; 180():430-448. PubMed ID: 31326599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of 6,9-dihydro-5H-pyrrolo[3,2-h]quinazolines as a new class of F508del-CFTR correctors for the treatment of cystic fibrosis.
    Barreca M; Renda M; Spanò V; Montalbano A; Raimondi MV; Giuffrida S; Bivacqua R; Bandiera T; Galietta LJV; Barraja P
    Eur J Med Chem; 2024 Oct; 276():116691. PubMed ID: 39089001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of novel thiazole- VX-809 hybrid derivatives as F508del correctors by QSAR-based filtering tools.
    Liessi N; Cichero E; Pesce E; Arkel M; Salis A; Tomati V; Paccagnella M; Damonte G; Tasso B; Galietta LJV; Pedemonte N; Fossa P; Millo E
    Eur J Med Chem; 2018 Jan; 144():179-200. PubMed ID: 29272749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting F508del-CFTR to develop rational new therapies for cystic fibrosis.
    Cai ZW; Liu J; Li HY; Sheppard DN
    Acta Pharmacol Sin; 2011 Jun; 32(6):693-701. PubMed ID: 21642944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.
    Meng X; Wang Y; Wang X; Wrennall JA; Rimington TL; Li H; Cai Z; Ford RC; Sheppard DN
    J Biol Chem; 2017 Mar; 292(9):3706-3719. PubMed ID: 28087700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Structure-activity Relationship of Aminoarylthiazole Derivatives as Potential Potentiators of the Chloride Transport Defect in Cystic Fibrosis.
    Liessi N; Pesce E; Salis A; Damonte G; Tasso B; Cichero E; Pedemonte N; Millo E
    Med Chem; 2021; 17(6):646-657. PubMed ID: 32141420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and SAR of 4-aminopyrrolidine-2-carboxylic acid correctors of CFTR for the treatment of cystic fibrosis.
    Scanio MJC; Searle XB; Liu B; Koenig JR; Altenbach RJ; Gfesser GA; Bogdan A; Greszler S; Zhao G; Singh A; Fan Y; Swensen AM; Vortherms T; Manelli A; Balut C; Gao W; Yong H; Schrimpf M; Tse C; Kym P; Wang X
    Bioorg Med Chem Lett; 2022 Sep; 72():128843. PubMed ID: 35688367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyanoquinolines with independent corrector and potentiator activities restore ΔPhe508-cystic fibrosis transmembrane conductance regulator chloride channel function in cystic fibrosis.
    Phuan PW; Yang B; Knapp JM; Wood AB; Lukacs GL; Kurth MJ; Verkman AS
    Mol Pharmacol; 2011 Oct; 80(4):683-93. PubMed ID: 21730204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Fused Pyrrolothiazole Systems as Correctors of Mutant CFTR Protein.
    Spanò V; Barreca M; Cilibrasi V; Genovese M; Renda M; Montalbano A; Galietta LJV; Barraja P
    Molecules; 2021 Feb; 26(5):. PubMed ID: 33652850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of CFTR Corrector and Potentiator Combination Therapy in Patients with Cystic Fibrosis for the F508del-CFTR Homozygous Mutation: A Systematic Review and Meta-analysis.
    Wu HX; Zhu M; Xiong XF; Wei J; Zhuo KQ; Cheng DY
    Adv Ther; 2019 Feb; 36(2):451-461. PubMed ID: 30554331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2.
    Bongiorno R; Ludovico A; Moran O; Baroni D
    Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trimethylangelicin promotes the functional rescue of mutant F508del CFTR protein in cystic fibrosis airway cells.
    Favia M; Mancini MT; Bezzerri V; Guerra L; Laselva O; Abbattiscianni AC; Debellis L; Reshkin SJ; Gambari R; Cabrini G; Casavola V
    Am J Physiol Lung Cell Mol Physiol; 2014 Jul; 307(1):L48-61. PubMed ID: 24816489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
    Bell SC; De Boeck K; Amaral MD
    Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of a hybrid potentiator-corrector agonist of the cystic fibrosis mutant protein DeltaF508-CFTR.
    Mills AD; Yoo C; Butler JD; Yang B; Verkman AS; Kurth MJ
    Bioorg Med Chem Lett; 2010 Jan; 20(1):87-91. PubMed ID: 19954980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants.
    Phuan PW; Tan JA; Rivera AA; Zlock L; Nielson DW; Finkbeiner WE; Haggie PM; Verkman AS
    Sci Rep; 2019 Nov; 9(1):17640. PubMed ID: 31776420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.